Hostname: page-component-7dd5485656-wjfd9 Total loading time: 0 Render date: 2025-10-31T14:59:28.018Z Has data issue: false hasContentIssue false
  • English
  • Français

Fluoxetine in post-traumatic stress disorder

Randomised, double-blind study

Published online by Cambridge University Press:  03 January 2018

Kathryn M. Connor ,
Suzanne M. Sutherland ,
Larry A. Tupler ,
Mary L. Malik ,
R. Jonathan  and
T. Davidson
Kathryn M. Connor*
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
Suzanne M. Sutherland
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
Larry A. Tupler
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
Mary L. Malik
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
R. Jonathan
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
T. Davidson
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
*
Dr Jonathan R. T. Davidson, Box 3812, Duke University Medical Center, Durham, NC 27710. Tel: 919-684-2880; Fax: 919-684-8866
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Most pharmacotherapy trials in post-traumatic stress disorder (PTSD) have been conducted upon male combat veterans. Outcome studies relating to civilians are therefore needed.

Aims

To demonstrate that fluoxetine is more effective than placebo in treating PTSD.

Method

Civilians with PTSD (n=53) were treated for 12 weeks with fluoxetine (up to 60 mg/day) or placebo. Assessments of PTSD severity, disability, stress vulnerability, and high end-state function were obtained.

Results

Fluoxetine was more effective than placebo on most measures at week 12, including global improvement (much or very much improved: fluoxetine 85%, placebo 62%, difference 0.24, 95% CI 0.01–0.47; very much improved: fluoxetine 59%, placebo 19%, difference 0.40, 95% CI 0.16–0.64), and high end-state function (fluoxetine 41%, placebo 4%, difference 0.37, 95% CI 0.17–0.57)

Conclusions

Fluoxetine was superior for measures of PTSD severity, disability, stress vulnerability, and high end-state function. The placebo-group response was low when viewed as a broad outcome based on a portfolio of ratings, but was higher with a traditional global rating criterion.

Information

Type
Papers
Information
The British Journal of Psychiatry , Volume 175 , Issue 1 , July 1999 , pp. 17 - 22
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Declaration of interest

This study was supported by a grant from the National Institute of Mental Health.

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.Google Scholar
American Psychiatrie Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington. DC: APA.Google Scholar
Davidson, J. R. T. (1997) Biological therapies for posttraumatic stress disorder: an overview. Journal of Clinical Psychiatry, 58 (suppl. 9), 29–32.Google Scholar
Davidson, J. R. T., Kudler, H., Smith, R. D., et al (1990) Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry, 47, 259–266.CrossRefGoogle ScholarPubMed
Davidson, J. R. T., Hughes, D., Blazer, D. G., et al (1991) Post-traumatic stress disorder in the community: an epidemiological study. Psychological Medicine. 21, 713–721.Google Scholar
Davidson, J. R. T. & Colket, J. T. (1997) The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder. International Clinical Psychopharmacology, 12, 41–45.Google Scholar
Davidson, J. R. T., Book, S. W., Colket, J. T., et al (1997a) Assessment of a new self-rating for post-traumatic stress disorder. Psychological Medicine, 27, 153–160.Google Scholar
Davidson, J. R. T., Malik, M. A. & Travers, J. (1997b) Structured Interview for PTSD (SIP): psychometric validation for DSM–IV criteria. Depression and Anxiety, 5, 1–3.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Davidson, J. R. T., Weisler, R. H., Malik, M., et al (1998) Fluvoxamine in civilians with posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 18, 93–95.CrossRefGoogle ScholarPubMed
Deakin, J. F. W. (1983) Roles of serotonergic systems in escape, avoidance and other behaviors. In Theory of Psychopharmacology, Volume 2 (ed. Cooper, S. J.), pp. 149–193. London: Academic Press.Google Scholar
Guy, W. (1977) ECDEU Assessment Manual for Psychopharmacology (DHEW publ. 76–338). pp. 217–222. Washington. DC: Department of Health. Education, and Welfare.Google Scholar
Hensman, R. J., Guimaraes, F. S., Wang, M., et al (1991) Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology, 104, 220–224.Google Scholar
Joseph, M. H. & Kennett, G. A. (1983) Corticosteroid response to stress depends upon increased tryptophan availability. Psychopharmacology, 79. 79–81.Google Scholar
Kessler, R. C., Sonnega, A., Bromet, E., et al (1995) Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry, 52, 1048–1060.Google Scholar
Kosten, T. R., Frank, J. B., Dan, E., et al (1991) Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease, 179, 366–370.Google Scholar
Sheehan, D. V. (1983) The Anxiety Disease. New York: Bantam.Google Scholar
Sheehan, D. V., Raj, A. B., Harnett Sheehan, K., et al (1990) Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology, 10, 3–11.CrossRefGoogle ScholarPubMed
Solomon, S. D. & Davidson, J. R. T. (1997) Trauma: prevalence, impairment, service use, and cost. Journal of Clinical Psychiatry, 58 (suppl. 9), 5–11.Google ScholarPubMed
Spitzer, R. L., Williams, J. B. W., Gibbon, M., et al (1988) Structured Clinical Interview for DSM–III–R – Patient Version (SCID–P). New York: New York State Psychiatric Institute.Google Scholar
van der Kolk, B. A., Dreyfuss, Di & Michaels, M. (1994) Fluoxetine in posttraumatic stress disorder. Journal of Clinical Psychiatry, 55, 517–522.Google ScholarPubMed
van Praag, H. M. (1996) Faulty cortisol/serotonin interplay. Psychopatholagical and biological characterization of a new, hypothetical depression subtype (SeCA depression). Psychiatry Research, 65, 143–157.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.